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Abstract: There has been an escalating interest in the medicinal use of Cannabis sativa in recent years. Cannabis 
is often administered orally with fat-containing foods, or in lipid-based pharmaceutical preparations. However, the 
impact of lipids on the exposure of patients to cannabis components has not been explored. Therefore, the aim of 
this study is to elucidate the effect of oral co-administration of lipids on the exposure to two main active cannabi-
noids, ∆9-tetrahydrocannabinol (THC) and cannabidiol (CBD). In this study, oral co-administration of lipids enhanced 
the systemic exposure of rats to THC and CBD by 2.5-fold and 3-fold, respectively, compared to lipid-free formula-
tions. In vitro lipolysis was conducted to explore the effect of lipids on the intestinal solubilisation of cannabinoids. 
More than 30% of THC and CBD were distributed into micellar fraction following lipolysis, suggesting that at least 
one-third of the administered dose will be available for absorption following co-administration with lipids. Both can-
nabinoids showed very high affinity for artificial CM-like particles, as well as for rat and human CM, suggesting high 
potential for intestinal lymphatic transport. Moreover, comparable affinity of cannabinoids for rat and human CM 
suggests that similar increased exposure effects may be expected in humans. In conclusion, co-administration of 
dietary lipids or pharmaceutical lipid excipients has the potential to substantially increase the exposure to orally 
administered cannabis and cannabis-based medicines. The increase in patient exposure to cannabinoids is of high 
clinical importance as it could affect the therapeutic effect, but also toxicity, of orally administered cannabis or 
cannabis-based medicines. 
Keywords: ∆9-tetrahydrocannabinol, cannabidiol, lymphatic transport, bioavailability, medicinal cannabis, dietary 
lipids 
Introduction
Cannabis sativa, commonly called hemp, has 
thousands of years-long history of medical use. 
Cannabis extracts were widely used in Europe 
and North America for their therapeutic value 
as sedatives, hypnotics, analgesics, muscle re- 
laxants, and anticonvulsant agents [1-3]. How- 
ever, cannabis was removed from British and 
American Pharmacopoeias in 20th century, par-
tially due to politic bias [4]. Although prohibited, 
many patients were nevertheless self-medicat-
ing to obtain therapeutic benefits from canna-
bis for various conditions, including AIDS wast-
ing syndrome, multiple sclerosis (MS) and spi- 
nal injuries [1, 4]. More recently, a growing inter-
est in the therapeutic effects of cannabis has 
developed following the isolation of cannabi-
noids, the principal chemical compounds of 
cannabis, as well as the discovery of endocan-
nabinoids and their cognate receptors in hu- 
mans [5-7]. These advances supported legali-
sation and wide-spread use of cannabis for 
therapeutic purposes in many countries. Cur- 
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rently, the use of cannabis for medicinal pur-
poses is legalised in 23 states of the US, as 
well as in Canada, the Netherlands, and Israel. 
In addition, the legalisation is currently under 
consideration in some other US states, as well 
as in Australia and New Zealand [8]. In Canada, 
the number of patients enrolled in the federal 
cannabis for therapeutic purposes program 
(28,115, as per Dec 2012) represents fewer 
than 5% of the estimated total users of medical 
cannabis in the country [9]. In the US, it is esti-
mated that there are currently more than one 
million legal medicinal cannabis users; the 
number of non-registered users, however, 
could be significantly higher (http://medicalm-
arijuana.procon.org/). 
Cannabis is typically consumed by either smok-
ing or oral ingestion. For many people, smoking 
is the preferred way of consuming medical can-
nabis as it allows tailoring of the dose to achieve 
rapid therapeutic effects [1]. However, this 
method of delivery is not appropriate in consid-
erable number of patients due to the irritant 
effects of some components in the smoke, the 
difficulty of consuming cannabis in smoke-free 
places, and other potential risks and difficulties 
associated with the smoking process [10]. Oral 
ingestion of cannabis or cannabis-based medi-
cines is therefore the preferred route of admin-
istration in many cases [1, 11]. When patients 
self-medicate with cannabis, it is frequently 
added to cookies or cakes. The vast majority of 
cannabis-cooking recipes involve the use of 
dietary lipids (whole milk, butter, or vegetable 
oil) for the preparation of these cannabis-con-
taining foods. This was attributed to the fact 
that therapeutically-active cannabinoids are 
lipid-soluble and therefore easily extracted 
from cannabis upon preparation with dietary 
fats [12]. It has also been proposed that the 
longer the fatty-acid chains in the lipids, the 
more potent cannabis-effect is expected fol-
lowing oral administration [12, 13].
The two main natural cannabinoids, the psy-
choactive ∆9-tetrahydrocannabinol (THC) and 
the non-psychoactive cannabidiol (CBD), have 
been the focus of research over the last few 
decades for their potential multiple therapeutic 
effects [14]. Both cannabinoids are currently 
available as pharmaceutical formulations. 
Nabiximols (Sativex®) is a commercially avail-
able oromucosal spray that contains a mixture 
of THC and CBD. It is used to alleviate spasticity 
in MS patients [15]. Dronabinol (Marinol®), the 
first oral preparation of synthetic THC, is app- 
roved to treat nausea and vomiting associated 
with cancer chemotherapy and to enhance 
appetite in AIDS patients suffering from weight 
loss. In addition, the FDA has recently approved 
Epidiolex® (an oral solution of CBD) as an 
orphan antiepileptic drug in the treatment of 
Dravet syndrome in children [16]. Oral formula-
tions of THC and CBD (Marinol® and Epidiolex®, 
respectively) contain sesame oil, which is most-
ly composed of long-chain triglycerides (LCT). It 
has been stated that the rationale for adding 
sesame oil to the formulations is to dissolve the 
lipid-soluble cannabinoids, THC and CBD [1, 
17]. Moreover, many clinical trials have also 
reported the use of vegetable oils as vehicles to 
prepare capsules containing cannabis extracts 
[18-21].
Thus, the available evidence suggests that the 
use of dietary fats and pharmaceutical lipid-
based excipients is common practice in the 
preparation of cannabis-containing foods and 
cannabis-based medicinal formulations. How- 
ever, despite the widespread use of lipids in 
cannabis formulations, to our knowledge the 
effect of lipid excipients on the exposure of 
patients to orally administered cannabis or can-
nabinoids has not been investigated. Therefore, 
the aim of this study is to elucidate the effect of 
oral co-administration of lipids on the exposure 
to the main cannabinoids, and hence on the 
therapeutic effect or potential toxicity of canna-
bis-based treatments. The possible mecha-
nisms underlying the impact of lipids on the 
systemic exposure to orally administered can-
nabinoids have also been investigated in this 
work.
Materials and methods 
Materials
THC (CAS: 1972-08-3) and CBD (CAS: 13956-
29-1) were donated by GW Pharmaceuticals 
(Cambridge, UK). 4,4-Dichlorodiphenyltrichlor- 
oethane (DDT, CAS: 50-29-3), probucol (CAS: 
23288-49-5), tris maleate, porcine pancreatin 
powder (8 × USP specifications), L-α-phospha- 
tidylcholine, sodium hydroxide, potassium bro-
mide (KBr), tetrahydrofuran (THF), and Intrali- 
pid® were purchased from Sigma Aldrich (Do- 
rset, UK). Sesame oil, peanut oil, taurocholic 
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acid salt hydrate, sodium chloride, acetonitrile 
(ACN), n-hexane, and water were purchased 
from Fisher Scientific (Leicestershire, UK). 
Vitamin D3 (CAS: 67-97-0) and calcium chloride 
were purchased from Alfa Aesar (Lancashire, 
UK). All reagents were of analytical grade or 
higher and used without further purification.
Pharmacokinetic experiments
The protocol for this study was approved by the 
UK Home Office in accordance with the Animals 
[Scientific Procedures] Act 1986. Male Sprague 
Dawley rats (Charles River Laboratories, UK) 
weighing 300-349 g were used in this study. 
The rats were housed in the University of 
Nottingham Bio Support Unit, and kept in a 
temperature-controlled, 12 hours light-dark 
cycle environment with free access to water 
and food.
The right external jugular vein was cannulated 
with a two-part catheter consisting of polyethyl-
ene (PE-50) connected to silastic tubing. Foll- 
owing an average recovery period of 36 hours, 
animals were divided into the following 6 treat-
ment groups: IV bolus of THC or CBD at a dose 
of 4 mg/kg (8 mg/mL solution in propylene 
glycol-ethanol-sterile water (80:10:10, v/v/v)), 
oral gavage of THC or CBD at a dose of 12 mg/
kg in lipid-free formulation (12 mg/mL solution 
in propylene glycol-ethanol-sterile water 
(80:10:10, v/v/v)), and oral gavage of THC or 
CBD in lipid (LCT)-based formulation at a dose 
of 12 mg/kg (12 mg/mL solution in sesame 
oil). Blood samples (0.25 mL) were then with-
drawn from the cannulae at 5, 15, 30, 60, 120, 
240, 360, 480, and 720 minutes after IV injec-
tions or 30, 60, 120, 180, 240, 300, 360, 480, 
and 720 minutes after oral administrations. 
Plasma was separated by centrifugation (3,000 
g, 10 minutes, 15°C) and stored at -80°C until 
analysis. Phoenix WinNonlin 6.3 (Pharsight, 
Mountain View, CA, USA) software was used for 
pharmacokinetic analysis of the data using a 
non-compartmental approach.
In vitro lipolysis
The effect of LCT on intestinal processing of 
lipophilic cannabinoids was assessed using an 
in vitro lipolysis model. This model simulates 
physiological lipid digestion processes in the 
small intestine, and is commonly used in the 
design and development of oral lipid-based 
drug delivery systems [22-26].
The in vitro lipolysis experiments used in this 
study were based on previously used and vali-
dated conditions [25]. The reaction vessel con-
tained 35.5 mL of the digestion buffer (50 mM 
tris maleate, 150 mM sodium chloride, and 5 
mM calcium chloride, pH = 6.8). Taurocholic 
acid salt hydrate and L-α-phosphatidylcholine 
were added to the buffer at concentrations of 5 
and 1.25 mM, respectively, to mimic a fasting 
gastrointestinal state. The vessel was attached 
to a pH-stat titrator (T50 Graphix, Mettler 
Toledo Inc,) and placed in a 37°C water bath. 
Cannabinoids were dissolved in LCT (sesame 
oil) to prepare 20 mg/mL solutions. A volume of 
160 µL of freshly prepared THC or CBD solution 
was dispersed in the reaction vessel and mixed 
for 15 minutes. Lipolysis was then initiated by 
the addition of 3.5 mL of pancreatin extract. 
Sodium hydroxide solution (1 M) was used as a 
titrant to maintain the pH of the reaction medi-
um at 6.8 (Electrode, DG111-SC pH). 
After completion of the lipolysis process, the 
resulting reaction medium was ultracentrifuged 
at 268,350 g (SORVALL® TH-641 Rotor, Thermo 
Fisher Scientific, UK) for 90 minutes at 37°C. 
Upper lipid, middle micellar, and lower sedi-
ment fractions were separated after centrifuga-
tion and stored at -80°C until analysis.
Association of cannabinoids with artificial 
chylomicron-like lipid particles and natural rat 
and human chylomicrons
Preparation of artificial lipid particle emulsions: 
Intralipid® 20% was used as a source of lipid 
particles as previously described [27]. Intrali- 
pid® is an emulsion of lipid particles that are 
composed of lecithin, soybean triglycerides 
and glycerin. Although natural chylomicrons 
(CM) have more complex structure, the uptake 
of lipophilic compounds by artificial emulsions 
has been shown to provide a reasonably close 
estimate for the degree of association with CM 
before proceeding with experiments that 
require materials from animals or humans [27, 
28].
Intralipid® was diluted with phosphate-buffered 
saline with a density of 1.006 g/mL and pH of 
7.4 to achieve a triglyceride (TG) concentration 
Systemic exposure to orally administered cannabinoids
3451 Am J Transl Res 2016;8(8):3448-3459
of 100 mg/dL. A TG enzymatic kit was used to 
assess TG concentration according to the man-
ufacturer’s protocol (Sigma Aldrich, Dorset, UK) 
using a BIO-TEK FL600™ plate reader (BIO-TEK 
INSTRUMENTS, INC. Vermont, USA). The lipid 
particle emulsion was then used to assess the 
uptake of THC and CBD as described below in 
the section on uptake experiments.
Preparation of rat plasma-derived chylomi-
crons
The protocol for this study was approved by the 
Home Office in accordance with the Animals 
[Scientific Procedures] Act 1986. Four male 
Sprague Dawley rats (Charles River Labora- 
tories, UK) weighing 275-300 g were used in 
this experiment. The rats were housed in the 
University of Nottingham Bio Support Unit, and 
kept in a temperature controlled, 12 hours 
light-dark cycle environment with free access to 
water and food.
CM separation from rat blood was performed 
as previously described [29]. Briefly, animals 
were fasted overnight with free access to water. 
Next morning, animals were administered 0.5 
mL peanut oil by oral gavage. Two more doses 
of peanut oil (0.3 mL each) were administered 
1 and 2 hours after the first administration. 
One hour after the last dose, animals were 
anesthetised with 2% isoflurane and a total 
blood volume of 10-12 mL was collected from 
the posterior vena cava of each animal. Plasma 
was separated from blood by centrifugation 
(800 g, 5 minutes, 15°C). KBr (0.57 g) was then 
added to 4 mL of plasma aliquots to adjust the 
density to 1.1 g/mL. Standard solutions with 
densities of 1.006, 1.019, and 1.063 g/mL 
were prepared and layered on top of plasma ali-
quots to build a density gradient in polyallomer 
ultracentrifuge tubes. Samples were ultracen-
trifuged at 268,350 g (SORVALL® TH-641 Rotor, 
Thermo Fisher Scientific, UK) for 35 minutes at 
15°C. Following ultracentrifugation, the top 1 
mL layer containing CM was collected using a 
glass pipette. TG concentration of CM emulsion 
was determined using a TG enzymatic kit 
(Sigma Aldrich, Dorset, UK) and BIO-TEK 
FL600™ plate reader (BIO-TEK INSTRUMENTS, 
INC. Vermont, USA). TG concentration was 
adjusted to 100 mg/dL by dilution with stan-
dard solution of 1.006 g/mL density. CM emul-
sion was kept at 4°C until uptake experiments 
(< 24 hours). 
Preparation of human plasma-derived chylomi-
cron emulsion 
The protocol for this experiment was approved 
by Faculty of Medicine and Health Sciences 
Research Ethics Committee, Queens Medical 
Centre, Nottingham University Hospitals, 
Nottingham, UK (BT12102015 CBS SoP). An 
exclusion criterion was the use of any medica-
tion within one week prior to the study. Three 
male healthy human volunteers (25-35 years 
old) were recruited for this study. After 12 ho- 
urs overnight fasting, participants had a high-
fat breakfast. Three to four hours following 
the meal (expected time of peak plasma-CM 
level [30, 31]) blood samples (30 mL) were col-
lected in heparinised tubes (Vacutainer® Blood 
Collection Tubes). Plasma was separated from 
blood by centrifugation (800 g, 10 minutes, 
15°C). CM separation was performed as 
described above for rat CM. The CM emulsion 
was kept at 4°C pending uptake experiments (< 
24 hours).
Uptake experiment
The uptake of THC and CBD by artificial lipid 
particles emulsion, rat CM emulsion, and hu- 
man CM emulsion was performed as previously 
described [29]. Briefly, stock solutions of THC 
and CBD (110.4 and 110.39 µg/mL, respec-
tively) were prepared in propylene glycol-etha-
nol (99:1, v/v). A volume of 10 µL of cannabi-
noid stock solution was added to 2 mL of the 
emulsion (100 mg/dL TG content) to achieve a 
molar concentration of 1.75 × 10-6 M. Emulsion, 
spiked with a cannabinoid, was then incuba- 
ted at 37°C for 1 hour with continuous mixing. 
Following incubation, the density of the emul-
sion was adjusted to 1.1 g/mL using KBr. 
Artificial lipid particles or natural CM were then 
separated by density gradient ultracentrifuga-
tion (SORVALL® TH-641 Rotor, Thermo Fisher 
Scientific, 268,350 g, 35 minutes, 15°C). The 
top 1 mL layer was collected following ultracen-
trifugation using a glass pipette and kept at 
-80°C for analysis. The cannabinoid content of 
this layer represents the fraction of the spiked 
dose associated with lipid artificial particles, 
rat CM, or human CM.
Analytical methods 
The concentrations of THC and CBD in rat plas-
ma, in vitro lipolysis fractions, artificial emul-
sion and CM samples were determined using a 
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Table 1. Chromatographic conditions for the detection of ∆9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in rat plasma, in vitro lipolysis 
medium fractions, artificial lipid particles emulsion, and chylomicrons (CM) emulsion using high performance liquid chromatography (HPLC)
Medium Mobile phase Stationary phase Flow rate (mL/min)
Oven tem-
perature (°C) IS
Detection wave-
length (nm)
THC Plasma ACN and Water (62:38, v/v) ACE C18-PFP 150 × 4.6 mm, 3 µm particle size 1 55 DDT 220
Lipolysis Methanol and Water (90:10, v/v) Phenomenex Luna C18(2) 150 × 2.1 mm, 5 µm 0.2 43 Vit D3 220
Lipid particles Methanol and Water (90:10, v/v) Phenomenex Luna C18(2) 150 × 2.1 mm, 5 µm 0.2 50 PB 220
Rat-CM Methanol and Water (90:10, v/v) Phenomenex Luna C18(2) 150 × 2.1 mm, 5 µm 0.2 50 PB 220
Human-CM ACN and Water (90:10, v/v) ACE Excel Super C18 100 × 4.6 mm, 5 µm 0.6 43 PB 220
CBD Plasma ACN and Water (62:38, v/v) ACE C18-PFP 150 × 4.6 mm, 3 µm particle size 1 55 DDT 220
Lipolysis ACN and Water (92:08, v/v) ACE Excel Super C18 100 × 4.6 mm, 5 µm 0.6 43 PB 210
Lipid particles ACN and Water (75:25, v/v) ACE Excel Super C18 100 × 4.6 mm, 5 µm 0.8 43 DDT 210
Rat-CM ACN and Water (75:25, v/v) ACE Excel Super C18 100 × 4.6 mm, 5 µm 0.8 43 DDT 210
Human-CM ACN and Water (75:25, v/v) ACE Excel Super C18 100 × 4.6 mm, 5 µm 0.8 43 DDT 210
IS, internal standard; DDT, 4,4-dichlorodiphenyltrichloroethane; PB, probucol. 
Systemic exposure to orally administered cannabinoids
3453 Am J Transl Res 2016;8(8):3448-3459
high performance liquid chromatography (HP- 
LC) system (Waters Alliance 2695 separations 
module) equipped with photodiode array ultra-
violet (UV) detector (Waters 996). Data pro-
cessing was carried out using EmpowerTM 2 
software. 
Plasma samples were analysed for cannabi-
noids concentrations using a previously devel-
oped and validated method [32]. Samples from 
in vitro lipolysis fractions (lipid, micellar, and 
sediment), artificial emulsion or CM association 
experiments were prepared for HPLC-UV analy-
sis by a liquid-liquid extraction method which 
was a slight modification of previously reported 
method for synthetic lipophilic cannabinoids 
(Table 1) [33]. Chromatographic conditions for 
the detection of THC and CBD in plasma, in 
vitro lipolysis fractions, artificial emulsion, and 
CM association samples are summarized in 
Table 1. 
The intra- and inter-day precision and accuracy 
for the detection of THC and CBD in lipolysis 
fractions, artificial lipid particles emulsion and 
CM were within acceptable limits in accordance 
with the FDA Guidance for Bioanalytical Method 
Validation (standard deviation (RSD) and rela-
tive error (RE) < 15% and within ± 15%, respec-
tively) [34]. 
Statistical analysis
Results are expressed as mean ± standard 
error of the mean (SEM). Statistical differences 
between data sets were assessed using either 
macokinetic parameters derived from these 
concentration-time profiles are summarised in 
Table 2. The absolute bioavailability of THC was 
increased by more than 2.5-fold following oral 
administration in the lipid-based formulation 
compared to lipid-free vehicle. 
The plasma concentration-time profiles follow-
ing the oral administration of CBD, the main 
non-psychoactive natural cannabinoid, in lipid-
free vehicle and lipid-based formulation are 
presented in Figure 2. The pharmacokinetic 
parameters derived from these concentration-
time profiles are summarised in Table 3. The 
absolute bioavailability of CBD was increased 
by almost 3-fold following oral administration in 
lipid-based formulation compared to lipid-free 
vehicle. 
Intraluminal processing of cannabinoids co-
administered with dietary fats or pharmaceuti-
cal lipid excipients
The intraluminal processing of cannabinoids 
co-administered with dietary fats or pharma-
ceutical lipid excipients has been assessed in 
this work using an in vitro lipolysis model. The 
results are shown in Figure 3. Upon lipolysis of 
sesame oil, around one-third of THC (31.2%, 
panel A) and CBD amounts (32.8%, Panel B) 
was observed to be solubilised in the micellar 
layer, which is the fraction readily available for 
absorption. The remaining approximately 70% 
of both compounds was distributed in the undi-
gested lipid fraction and the sediment layer 
Figure 1. Plasma concentration-time profiles of ∆9-tetrahydrocannabinol 
(THC) following IV bolus (4 mg/kg, n = 5), oral lipid-free formulation (12 mg/
kg, n = 6), and oral long-chain triglyceride (LCT)-based formulation (12 mg/
kg, n = 5) to rats. The data are shown as mean ± SEM.
one-way ANOVA or unpaired 
two-tailed Student’s t-test, as 
appropriate. A p value < 0.05 
was considered to represent 
a significant difference. 
Results
Effect of lipids on systemic 
exposure to orally adminis-
tered cannabinoids
The plasma concentration-
time profiles following oral 
administration of THC, the 
main psychoactive natural 
cannabinoid, in lipid-free vehi-
cle and lipid-based formula-
tion are presented in Figure 
1. IV bolus administration was 
used to calculate the abso-
lute bioavailability. The phar-
Systemic exposure to orally administered cannabinoids
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which are considered to represent the propor-
tion of the drug not readily available for absorp-
tion following oral administration with lipids 
[35, 36].
Intestinal lymphatic transport potential of can-
nabinoids
The intestinal lymphatic transport potential of 
THC and CBD was assessed using incubation 
studies with artificial lipid emulsion and with 
natural rat and human CM [27, 29]. The results 
of the uptake are shown in Figure 4. The asso-
ciation values of both cannabinoids with artifi-
cial lipid particles and natural CM were in the 
range of 70-80%. No significant differences 
were seen between the uptake of cannabinoids 
by artificial lipid particles, rat CM or human CM 
(Figure 4).
Discussion
Over the last few years, the medicinal use of 
cannabis has gained growing interest after a 
ever, the impact of dietary fats or pharmaceuti-
cal lipid excipients on the systemic exposure of 
patients to the cannabinoids has not previously 
been explored. This could be of particular 
importance when it comes to therapeutic effi-
cacy or potential toxicity. In this study we aimed 
to assess the effect of lipids on the systemic 
exposure to the main constituents of cannabis, 
THC and CBD, following oral consumption of 
cannabis with dietary fats or oral administra-
tion of cannabis-based medicines. 
Our results show that the co-administration of 
cannabinoids with lipids enhances the bioavail-
ability of THC in rats by more than 2.5-fold 
(Figure 1 and Table 2) and of CBD by almost 
3-fold (Figure 2 and Table 3). Such a profound 
increase in systemic exposure can significantly 
affect the therapeutic effects or toxicity of 
these cannabinoids.
To the best of our knowledge there are no previ-
ously reported studies of absolute oral bioavail-
Table 2. Pharmacokinetic parameters (mean ± SEM) derived from plasma concentration-time profiles 
following the administration of IV bolus (4 mg/kg), oral lipid-free formulation (12 mg/kg), and long 
chain triglyceride (LCT)-based formulation (12 mg/kg) of ∆9-tetrahydrocannabinol (THC) to rats 
Administration/formulation AUC0-t (h.ng/mL) Vd (mL/kg) CL (mL/h/kg) t1/2 (h) Cmax (ng/mL) Tmax (h) F (%) n
IV bolus 1624 ± 334 7921 ± 462 2671 ± 680 4.6 ± 2.0 - - - 5
Oral lipid-free 414 ± 130 - - 6.9 ± 2.0 65 ± 17 2 8.5 ± 2.6 6
Oral LCT-based 1050 ± 169* - - 7.4 ± 2.6 172 ± 34 3 21.5 ± 3.5* 5
Unpaired t-test was used for statistical analysis. *Statistically different from oral lipid-free formulation (P < 0.05).
Figure 2. Plasma concentration-time profiles of cannabidiol (CBD) following 
IV bolus (4 mg/kg, n = 4), oral lipid-free formulation (12 mg/kg, n = 4), and 
long-chain triglyceride (LCT)-based formulation (12 mg/kg, n = 4) to rats. The 
data are shown as mean ± SEM.
long period of marginalization 
[9]. The legalisation of medi-
cal cannabis programs has 
noticeably increased the ac- 
cess of patients to cannabis 
and cannabis-based medi-
cines in many countries [8]. 
For many patients, orally ad- 
ministered cannabis and can-
nabis-based medicines are 
preferred [1, 11]. Orally admi- 
nistered cannabis is often 
consumed with dietary fat-
containing food (such as 
cookies). Lipids are also com-
monly used in pharmaceutical 
formulations of cannabis or 
cannabinoids. The rationale 
for the use of dietary fats and 
lipids is to enhance the extrac-
tion of the lipid-soluble active 
constituents [1, 12, 13]. How- 
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ability of these cannabinoids in rats. In humans, 
the reported bioavailabilities of THC and CBD, 
based on a very limited available number of 
studies, were less than 10% [37-39]. In our 
study, oral administration of THC and CBD in 
lipid-free formulations to rats showed similar 
range of bioavailability to that reported in 
humans (Tables 2 and 3). 
To explore the mechanism(s) by which lipids 
could enhance the oral bioavailability of THC 
and CBD, we first assessed the effect of lipids 
on intraluminal (intestinal) solubilisation of can-
nabinoids using in vitro lipolysis experiments. 
In vitro lipolysis is a commonly used model in 
pharmaceutics to assess the intraluminal pro-
cessing of drugs administered orally with lipid-
based formulation, or following high-fat meals 
[26]. The results of our lipolysis experiments 
showed that around one-third of THC and CBD 
was solubilised in mixed micelles. These spher-
ical structures are created as a result of lipid 
digestion process and have the ability to solu-
bilise lipophilic compounds in aqueous medi-
um, and thus could facilitate the diffusion and 
absorption of lipophilic drugs (Figure 3A and 
3B, respectively). The remaining two-thirds of 
THC and CBD were retained within the undi-
gested lipids and the sediment layer. This sug-
gests that two-thirds of the administered dose 
of THC and CBD is not readily available for 
absorption when cannabinoids are adminis-
tered orally in the presence of lipids. Long 
intestinal transit times and increased bile salt 
and phospholipid levels due to concomitant 
food intake might permit more efficient solubili-
sation of the drugs in vivo [35].
To assess post-luminal (inside the enterocytes) 
effects of lipids on the absorption of THC and 
CBD, we evaluated the role of the intestinal 
lymphatic transport in the absorption process 
Table 3. Pharmacokinetic parameters (mean ± SEM) derived from plasma concentration-time profiles 
following the administration of IV bolus (4 mg/kg), oral lipid-free formulation (12 mg/kg), and long 
chain triglyceride (LCT)-based formulation (12 mg/kg) of cannabidiol (CBD) to rats
Administration/formulation AUC0-t (h.ng/mL) Vd (mL/kg) CL (mL/h/kg) t1/2 (h) Cmax (ng/mL) Tmax (h) F (%) n
IV bolus 1380 ± 43 12495 ± 2607 2794 ± 85 2.0 ± 0.1 - - - 4
Oral lipid-free 327 ± 91 - - 2.5 ± 0.4 87 ± 25 3 7.9 ± 2.2 4
Oral LCT-based 932 ± 188* - - 1.6 ± 0.1 308 ± 109 3 22.3 ± 4.6* 4
Unpaired t-test was used for statistical analysis. *Statistically different from oral lipid-free formulation (P < 0.05).
Figure 3. Panel A: Distribution of ∆9-tetrahydrocannabinol (THC) in the micellar, lipid, and sediment layers after 
lipolysis of 160 μL of the long-chain triglyceride (LCT) sesame oil containing 20 mg of THC (n = 6). Panel B: Distribu-
tion of cannabidiol (CBD) in the micellar, lipid, and sediment layers after lipolysis of 160 μL of the LCT sesame oil 
containing 20 mg of CBD (n = 6). The data are shown as mean ± SEM. One-way ANOVA with Tukeys post-hoc test 
was used for statistical analysis. ****P < 0.0001. 
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of cannabinoids. The absorption of dietary lip-
ids (in the form LCT) involves the formation of 
CM in enterocytes (Figure 5). The association 
of lipophilic compounds with CM in the entero-
cyte is a pre-requisite for their intestinal lym-
phatic transport. The affinity of compounds for 
CM ex vivo has previously been shown to be 
predictive for the intestinal lymphatic absorp-
tion of drugs [29]. In this study, the lymphatic 
transport potential was initially investigated by 
assessing the uptake of THC and CBD by artifi-
cial CM-like lipid particles. Both compounds 
showed remarkable association with lipid par-
ticles (> 76%). However, lipid particles lack the 
surface apoproteins found in natural CM which 
might affect the process of association [27]. 
Association experiments were also performed 
with natural CM isolated from rats and showed 
association values of 72.5 ± 3.6% and 73.7 ± 
3.6% for THC (Figure 4A) and CBD (Figure 4B), 
respectively. Therefore, the data suggest that 
CM serve as carriers to transfer THC and CBD 
to the systemic circulation via the intestinal 
lymphatic system following oral administration 
with lipids. Drugs that are transported via the 
intestinal lymphatic system avoid hepatic first-
pass metabolism and therefore achieve signifi-
cantly higher bioavailability than after adminis-
tration in lipid-free formulation (Figure 5). It has 
previously been suggested that THC and CBD 
Figure 4. Panel A: Uptake of ∆9-tetrahydrocannabinol (THC) by lipid particles (from Intralipid®, n = 6) and plasma 
derived chylomicrons (CM) isolated from rats (n = 5) or humans (n = 6). Panel B: Uptake of cannabidiol (CBD) by lipid 
particles (n = 9) and plasma derived CM isolated from rats (n = 7) or humans (n = 5). The data are shown as mean 
± SEM of % association. One-way ANOVA with Tukey’s post-hoc test was used for statistical analysis. Differences 
between data sets were statistically non-significant.
Figure 5. Schematic representation of the proposed mechanism for the intestinal lymphatic transport of ∆9-tetrahy-
drocannabinol (THC) and cannabidiol (CBD) following oral co-administration with dietary fats of long-chain triglycer-
ides (LCT). (1) Intestinal solubilisation of THC and CBD in the mixed micelles as a result of lipid digestion process. 
(2) Uptake of cannabinoids by the chylomicrons (CM) inside the enterocytes. (3) Transfer of THC and CBD by CM to 
the systemic circulation via the intestinal lymphatic system avoiding hepatic first-pass metabolism.
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exhibit substantial first-pass metabolism [40, 
41]. Indeed, higher bioavailabilites were report-
ed after administration by routes that avoid 
first-pass metabolism such as inhalation of 
THC [37, 42] and CBD [39], or rectal administra-
tion of THC [40]. Comparable results were 
reported previously for the synthetic lipophilic 
cannabinoid PRS-211,220, which had 66% 
association with rat CM, and showed 3-fold 
increase in oral bioavailability following oral 
administration with LCT compared to lipid-free 
formulation [33]. In addition, it was found in 
that study that about two-thirds of the absolute 
bioavailability of PRS-211,220 was solely due 
to a contribution of the intestinal lymphatic 
transport. These observations support our pro-
posed mechanism of intestinal lymphatic trans-
port as a primary mechanism underlying the 
enhanced exposure to THC and CBD when co-
administered with LCT in rats. In order to assess 
if intestinal lymphatic transport might affect 
bioavailability of cannabinoids in humans, the 
uptake of THC and CBD by CM isolated from 
human volunteers was also assessed in our 
study. Association values observed in these 
experiments were similar to the uptake profile 
seen in rat CM (Figure 4). Therefore, it is rea-
sonable to assume that similar effects of 
increased systemic exposure to orally adminis-
tered cannabinoids when co-administered with 
lipids would occur in humans.
It is unclear if there is a minimal volume of lip-
ids that is required to activate intestinal lym-
phatic transport mechanism. Some studies 
show that as little as 1 g of lipid emulsion was 
sufficient to activate intestinal lymphatic trans-
port of a highly lipophilic compound in dogs 
[43]. In contrast, it has been demonstrated that 
the administration of a low dose of lipids to rats 
(equivalent to 1 g in humans) was not sufficient 
to enhance intestinal lymph flow. However, a 
higher lipid dose (equivalent to 10 g in humans) 
significantly increased lymph flow [44]. These 
amounts of lipids can easily be obtained from 
the average meal in Western diet [45]. It cur-
rently remains unclear if the administration of a 
small-volume capsule with lipid-based formula-
tion of cannabinoids (such as Marinol®) in fast- 
ing conditions would activate lymphatic trans- 
port and increase significantly the bioavailability 
of cannabinoids. Indeed, low bioavailability of 
cannabinoids were reported in humans after 
oral administration in low volumes of lipid-ba- 
sed formulations (0.25-0.5 mL capsules con-
taining the drug dissolved in sesame oil) under 
fasting conditions [38, 46]. However, our res- 
ults suggest that the same lipid-based formula-
tion-containing capsule administered with a 
meal, or lipid-rich cannabis-containing cookies, 
may result in a profound increase in systemic 
exposure, similar to what has been observed in 
this study in a rat model.
Conclusions
In conclusion, co-administration of dietary lip-
ids or pharmaceutical lipid excipients may sub-
stantially increase the systemic exposure to 
orally administered cannabis or cannabis-
based medicines. Our data suggest that the 
primary mechanism of the increased absorp-
tion of cannabinoids in the presence of lipids is 
intestinal lymphatic transport. The amount of 
lipids present in cannabis-containing foods, or 
following a high-fat meal, is sufficient to acti-
vate intestinal lymphatic transport and lead to 
increased systemic exposure to cannabinoids. 
The increase in systemic exposure to cannabi-
noids in humans is of potentially high clinical 
importance as it could turn a barely effective 
dose of orally administered cannabis into a 
highly effective one, or indeed a therapeutic 
dose into a toxic one. Therefore, it is important 
for cannabis-prescribing clinicians and those 
who self-medicate with cannabis to carefully 
consider the effect of the co-administration of 
lipids on the therapeutic outcomes of orally 
administered cannabis or cannabis-based 
medicines.
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